# US 2026/0083848 A1 · Combination of car t-cell therapy with btk inhibitors and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083848 A1
- Document ID: US20260083848A1
- Status: Published application
- Kind: A1
- Application number: 18/706,903
- Filed: 2022-11-02
- Published: 2026-03-26
- Earliest claimed: 2021-11-03
- Assignees: Viracta Therapeutics, Inc.
- Applicants: Viracta Therapeutics, Inc.
- Inventors: Judith A. FOX; Pietro TAVERNA
- Web page: https://patentgrep.com/patent/US20260083848A1

## CPC

- A61K 40/4211: {CD19 or B4}
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides the use of immune effector cells (e.g., T-cells or NK cells) engineered to express a Chimeric Antigen Receptor (CAR), in combination with a kinase inhibitor (e.g., a BTK inhibitor), for the treatment of a disease or disorder (e.g., a hematological malignancies).

## Claims

### Claim 1

Use of immune effector cells engineered to express a Chimeric Antigen Receptor (CAR), in combination with a kinase inhibitor, for the treatment of a disease or disorder in a subject in need thereof.

### Claim 2

A combination comprising:
a. immune effector cells engineered to express a Chimeric Antigen Receptor (CAR); and
b. a BTK inhibitor.

### Claim 3 (depends on 2)

A method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the combination of claim 2.

### Claim 4 (depends on 2)

A combination of claim 2 for use in treating or preventing a disease or disorder.

### Claim 5 (depends on 2)

Use of the combination of claim 2 in the manufacture of a medicament for treating or preventing a disease or disorder.

### Claim 6 (depends on 2, 3, 4, 5)

The method, use, or combination for use of any one of claims 2-5, wherein the immune effector cells are T-cells.

### Claim 7 (depends on 6)

The method, use, or combination for use of claim 6, wherein the T-cells are CD19 CAR T-cells.

### Claim 8 (depends on 2, 3, 4, 5, 6, 7)

The method, use, or combination for use of any one of claims 2-7, wherein the kinase inhibitor is a BTK inhibitor.

### Claim 9 (depends on 2, 3, 4, 5, 6, 7, 8)

The method, use, or combination for use of any one of claims 2-8, wherein the BTK inhibitor is a reversible BTK inhibitor.

### Claim 10 (depends on 8, 9)

The method, use, or combination for use of claim 8 or claim 9, wherein the BTK inhibitor is vecabrutinib.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method, use, or combination for use of any one of claims 1-10, wherein the disease or disorder is a hematological malignancy.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method, use, or combination for use of any one of claims 1-11, wherein the BTK inhibitor ameliorates toxicities after CAR T-cell (CART) therapy.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method, use, or combination for use of any one of claims 1-12, wherein the BTK inhibitor ameliorates cytokine release syndrome (CRS) severity or prevents CRS after CAR T-cell therapy.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method, use, or combination for use of any one of claims 1-12, wherein the BTK inhibitor ameliorates neurotoxicity (NT) or prevents NT after CAR T-cell therapy.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method, use, or combination for use of any one of claims 1-14, wherein the BTK inhibitor does not significantly impair anti-tumor effect of the CART therapy.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method, use, or combination for use of any one of claims 1-15, wherein the BTK inhibitor increases in vivo proliferation of CART cells.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method, use, or combination for use of any one of claims 1-15, wherein the BTK inhibitor increases in vivo expansion of CART cells.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method, use, or combination for use of any one of claims 1-15, wherein the BTK inhibitor reduces in vivo immune suppression of CART cells.

### Claim 19

A method for treating or delaying progression of a cancer in a subject comprising administering to the subject a therapeutically effective amount of a reversible BTK inhibitor, wherein the subject is receiving or has received a CART cell therapy that specifically targets an antigen associated with or expressed by a plurality of cancer cells.

### Claim 20

A method of inducing or promoting an anti-tumor immune response in a subject with a cancer, comprising administering to the subject a therapeutically effective amount of a reversible BTK inhibitor, wherein the subject is receiving or has received a CART cell therapy that specifically targets an antigen associated with or expressed by a plurality of cancer cells.

### Claim 21

A method of increasing activation, proliferation, and/or expansion of CART cells in a subject having a cancer, comprising administering to the subject a therapeutically effective amount of a reversible BTK inhibitor, wherein the subject is receiving or has received a CART cell therapy that specifically targets an antigen associated with or expressed by a plurality of cancer cells.

### Claim 22 (depends on 19, 20, 21)

The method of any one of claims 19-21, wherein the subject is administered the reversible BTK inhibitor prior to receiving the CART cell therapy.

### Claim 23 (depends on 19, 20, 21)

The method of any one of claims 19-21, wherein the subject is administered the reversible BTK inhibitor after receiving the CART cell therapy.

### Claim 24 (depends on 19, 20, 21)

The method of any one of claims 19-21, wherein the reversible BTK inhibitor and CART cell therapy are administered simultaneously.

### Claim 25 (depends on 19, 20, 21, 22, 23, 24)

The method of any one of claims 19-24, wherein the cancer is a hematological malignancy.

### Claim 26 (depends on 25)

The method of claim 25, wherein the hematological malignancy comprises a B cell malignancy.

### Claim 27 (depends on 26)

The method of claim 26, wherein the B cell malignancy is a leukemia, a lymphoma, or a myeloma.

### Claim 28 (depends on 26, 27)

The method of claim 26 or claim 27, wherein the B cell malignancy is non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), lymphoplasmacytoid lymphoma (LL), Waldenstrom macroglobulinemia (MG), mantle-cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), acute myeloid leukemia (AML), or multiple myeloma.

### Claim 29 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 19-28, wherein the antigen is a B cell antigen.

### Claim 30 (depends on 29)

The method of claim 29, wherein the B cell antigen is selected from CD10, CD19, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, and CD79a.

### Claim 31 (depends on 29, 30)

The method of claim 29 or claim 30, wherein the B cell antigen is CD19.

### Claim 32 (depends on 31)

The method of claim 31, wherein the CART cell therapy is selected from Kymriah™, Tecartus™, Breyanzi™, and Yescarta™.

### Claim 33 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 19-32, wherein the subject is human.

### Claim 34

A kit comprising a container comprising a composition comprising a reversible BTK inhibitor, and optionally a pharmaceutically acceptable carrier, and a package insert comprising instructions for administration of the reversible BTK inhibitor for treating or delaying progression of cancer in a subject receiving CART cell therapy.

### Claim 35

A kit comprising a medicament comprising a composition comprising a reversible BTK inhibitor, and optionally a pharmaceutically acceptable carrier, and a package insert comprising instructions for administration of the reversible BTK inhibitor for treating or delaying progression of cancer in a subject receiving CART cell therapy.

### Claim 36

A kit comprising a container comprising a composition comprising a reversible BTK inhibitor, and optionally a pharmaceutically acceptable carrier, and a package insert comprising instructions for administration of the reversible BTK inhibitor for inducing or promoting an anti-tumor immune response in a subject receiving CART cell therapy.

### Claim 37

A kit comprising a medicament comprising a composition comprising a reversible BTK inhibitor, and optionally a pharmaceutically acceptable carrier, and a package insert comprising instructions for administration of the reversible BTK inhibitor for inducing or promoting an anti-tumor immune response in a subject receiving CART cell therapy.

### Claim 38

A kit comprising a container comprising a composition comprising a reversible BTK inhibitor, and optionally a pharmaceutically acceptable carrier, and a package insert comprising instructions for administration of the reversible BTK inhibitor for increasing activation, proliferation, and/or expansion of CART cells in a subject receiving CART cell therapy.

### Claim 39

A kit comprising a medicament comprising a composition comprising a reversible BTK inhibitor, and optionally a pharmaceutically acceptable carrier, and a package insert comprising instructions for administration of the reversible BTK inhibitor for increasing activation, proliferation, and/or expansion of CART cells in a subject receiving CART cell therapy.

### Claim 40

Use of a reversible BTK inhibitor for treating or delaying progression of a cancer in a subject receiving or that has received a CART cell therapy.

### Claim 41

Use of a reversible BTK inhibitor in the manufacture of a medicament for treating or delaying progression of a cancer in a subject receiving or that has received a CART cell therapy.

### Claim 42

Use of a reversible BTK inhibitor for inducing or promoting an anti-tumor immune response in a subject receiving or that has received a CART cell therapy.

### Claim 43

Use of a reversible BTK inhibitor in the manufacture of a medicament for inducing or promoting an anti-tumor immune response in a subject receiving or that has received a CART cell therapy.

### Claim 44

Use of a reversible BTK inhibitor for increasing activation, proliferation, and/or expansion of CART cells in a subject receiving or has received a CART cell therapy.

### Claim 45

Use of a reversible BTK inhibitor in the manufacture of a medicament for increasing activation, proliferation, and/or expansion of CART cells in a subject receiving or has received a CART cell therapy.

### Claim 46 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The method of any one of claims 19-33, the kit of any one of claims 34-39, or the use of any one of claims 40-45, wherein the reversible BTK inhibitor selectively inhibits BTK with a half-maximal inhibitory concentration (IC50) of less than about 100 nM, about 90 nM, about 80 nM, about 70 nM, about 60 nM, about 50 nM, about 40 nM, about 30 nM, or about 20 nM.

### Claim 47 (depends on 46)

The method, kit, or use of claim 46, wherein the reversible BTK inhibitor inhibits ITK.

### Claim 48 (depends on 47)

The method, kit, or use of claim 47, wherein the reversible BTK inhibitor inhibits ITK with a half-maximal inhibitory concentration (IC50) of less than about 100 nM, about 90 nM, about 80 nM, about 70 nM, about 60 nM, about 50 nM, about 40 nM, about 30 nM, or about 20 nM.

### Claim 49 (depends on 46, 47, 48)

The method, kit, or use of any one of claims 46-48, wherein the reversible BTK inhibitor inhibits BTK comprising a mutation selected from C481R and C481S.

### Claim 50 (depends on 46, 47, 48, 49)

The method, kit, or use of any one of claims 46-49, wherein the reversible BTK inhibitor is vecabrutinib.
